SCHEMBL17899852

SCHEMBL17899852

CCOC(=O)C(C)(C)Sc1ccc2cnsc2c1-c1ccc(SC)nc1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 12/20 0.52
ALDH1A1 P00352 4/20 0.33
TP53 P04637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19449100 0.89 SLC22A12 (0.55) SLC22A12ALDH1A1TP53NPSR1MEN1
SCHEMBL19562887 0.89 SLC22A12 (0.54) SLC22A12ALDH1A1TP53NPSR1MEN1
SCHEMBL17899879 0.83 SLC22A12 (0.58) SLC22A12ALDH1A1NPSR1MEN1POLB
SCHEMBL17899840 0.82 SLC22A12 (0.68) SLC22A12
SCHEMBL19547903 0.81 SLC22A12 (0.50) SLC22A12
SCHEMBL17899849 0.81 SLC22A12 (0.75) SLC22A12ALDH1A1MAPTRAB9A
SCHEMBL19435490 0.77 SLC22A12 (0.62) SLC22A12ALDH1A1
SCHEMBL19547901 0.75 SLC22A12 (0.43) SLC22A12
SCHEMBL19435498 0.74 SLC22A12 (0.77) SLC22A12ALDH1A1NPSR1NPC1MAPT
SCHEMBL17899933 0.74 SLC22A12 (0.57) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP claimed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN claimed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US claimed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885ALDH1A1 673/4885TP53 3739/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885ALDH1A1 672/4885TP53 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.